You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 143 No. 5, May 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Observation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Genetics
 •Genetic Disorders
 •Ophthalmology
 •Retinal/ Chorioretinal Disorders
 •Neoplasms
 •Phototherapy
 •Drug Therapy
 •Adverse Effects
 •Alert me on articles by topic

Retinal Toxic Reactions Following Photopheresis

Jose Manuel Vagace, MD, PhD; Guillermo Gervasini, PharmD, PhD; Fernando Morais, MD; Julio Benitez, MD, PhD; Nieves Alonso, MD; Diego de Argila, MD; Isabel Arranz, MD; Roberto Bajo, MD, PhD

Arch Dermatol. 2007;143(5):622-625.

Background  Extracorporeal photochemotherapy (ECP), also known as photopheresis, is a generally well-tolerated therapeutic, immunomodulatory approach successfully used in cutaneous T-cell lymphoma and other diseases produced by T-lymphocytes such as graft vs host disease.

Observations  On 2 separate occasions, a 54-year-old white man with Sézary syndrome developed cutaneous phototoxic reactions and chorioretinitis after being treated with ECP. A pharmacokinetic study showed therapeutic blood levels of 8-methoxypsoralen as long as 18 weeks after therapy had been terminated. However, the analysis of mutations in genes involved in the drug's disposition could not explain these abnormal levels.

Conclusions  To our knowledge, there has been no previous description of ECP-related retinal toxic effects. This adverse effect was probably linked to impaired drug elimination. Further studies would be needed to determine the underlying mechanism.


Author Affiliations: Departments of Hematology (Drs Vagace, Alonso, and Bajo) and Dermatology, (Dr de Argila), University Hospital Infanta Cristina, Badajoz, Spain; Department of Pharmacology, University of Extremadura, Badajoz (Drs Gervasini and Benitez); Department of Ophthalmology, Hospital of Merida, Merida, Spain (Dr Morais); and Department of Biochemistry, Hospital Ramón y Cajal, Madrid, Spain (Dr Arranz).







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.